The latest on new drugs, approvals, and regulation across the GLP-1 space.
9 articles in this category.
Medicare GLP-1 coverage is NOW LIVE as of July 1, 2026. Here's who qualifies for the $50/month Bridge program, how to get prior auth, and whether the Bridge beats cash-pay (our 49-provider price audit).
CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.
Updated June 10, 2026 (ADA 2026 full dataset): Retatrutide Phase 3 program complete. Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. Comorbidities (ADA June 2026): TRIUMPH-4 knee OA, WOMAC pain score −4.0 points (≈75% reduction) vs −2.1 placebo; 14.1% pain-free on 9mg vs 4.2% placebo. TRIUMPH-1 OSA secondary: 60.6% AHI reduction (58.6 → ~23 events/hr). NDA expected Q4 2026.
Verified May 8, 2026, Updated June 29, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, forever, not just during shortage enforcement. Public comment period extended to July 30, 2026 (from June 29 via Federal Register 2026-12937, published June 26, 2026). If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.
Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.
HHS Secretary Robert F. Kennedy Jr. is considering a regulatory framework for Medicare and Medicaid GLP-1 coverage, but only for patients who have 'exhausted other options', specifically glucose monitors (~$80/month), diet changes, and exercise. Verified April 2026: what Kennedy said on CBS News April 15 and at the House Ways and Means hearing April 16, how the gate would work, and how it stacks with the already-announced Medicare GLP-1 Bridge launching July 2026.
Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.
Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounders between March 12 and April 8, 2026, the largest enforcement wave since the semaglutide compounding ban. Full list of affected pharmacies, what they violated, and what to do if you were a patient.
The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Ready to pick a provider? Take the 60-second match quiz or browse our full GLP-1 provider rankings.
Four affiliate partners we feature, we may earn a commission.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.